Skip to main content
Top
Published in: Trials 1/2011

Open Access 01-12-2011 | Commentary

Why we need easy access to all data from all clinical trials and how to accomplish it

Author: Peter C Gøtzsche

Published in: Trials | Issue 1/2011

Login to get access

Abstract

International calls for registering all trials involving humans and for sharing the results, and sometimes also the raw data and the trial protocols, have increased in recent years. Such calls have come, for example, from the Organization for Economic Cooperation and Development (OECD), the World Health Organization (WHO), the US National Institutes of Heath, the US Congress, the European Commission, the European ombudsman, journal editors, The Cochrane Collaboration, and several funders, for example the UK Medical Research Council, the Wellcome Trust, the Bill and Melinda Gates Foundation and the Hewlett Foundation.
Calls for data sharing have mostly been restricted to publicly-funded research, but I argue that the distinction between publicly-funded and industry-funded research is an artificial and irrelevant one, as the interests of the patients must override commercial interests.
I also argue why it is a moral imperative to render all results from all trials involving humans, also healthy volunteers, publicly available. Respect for trial participants who often run a personal and unknown risk by participating in trials requires that they - and therefore also the society at large that they represent - be seen as the ultimate owners of trial data.
Data sharing would lead to tremendous benefits for patients, progress in science, and rational use of healthcare resources based on evidence we can trust. The harmful consequences are minor compared to the benefits. It has been amply documented that the current situation, with selective reporting of favorable research and biased data analyses being the norm rather than the exception, is harmful to patients and has led to the death of tens of thousands of patients that could have been avoided.
National and supranational legislation is needed to make data sharing happen as guidelines and other voluntary agreements do not work. I propose the contents of such legislation and of appropriate sanctions to hold accountable those who refuse to share their data.
Literature
2.
go back to reference Gøtzsche PC: Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal, anti-inflammatory drugs in rheumatoid arthritis. Control Clin Trials. 1989, 10: 31-56. 10.1016/0197-2456(89)90017-2. (amendment:356)PubMed Gøtzsche PC: Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal, anti-inflammatory drugs in rheumatoid arthritis. Control Clin Trials. 1989, 10: 31-56. 10.1016/0197-2456(89)90017-2. (amendment:356)PubMed
3.
go back to reference Gøtzsche PC: Bias in double-blind trials. Dan Med Bull. 1990, 37: 329-36.PubMed Gøtzsche PC: Bias in double-blind trials. Dan Med Bull. 1990, 37: 329-36.PubMed
4.
go back to reference Bero LA, Rennie D: Influences on the quality of published drug studies. Int J Technol Assess Health Care. 1996, 12: 209-237. 10.1017/S0266462300009582.PubMed Bero LA, Rennie D: Influences on the quality of published drug studies. Int J Technol Assess Health Care. 1996, 12: 209-237. 10.1017/S0266462300009582.PubMed
5.
go back to reference Safer DJ: Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. J Nerv Ment Dis. 2002, 190: 583-592. 10.1097/00005053-200209000-00002.PubMed Safer DJ: Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. J Nerv Ment Dis. 2002, 190: 583-592. 10.1097/00005053-200209000-00002.PubMed
6.
go back to reference Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B: Evidence b(i)ased medicine - selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ. 2003, 326: 1171-1173. 10.1136/bmj.326.7400.1171.PubMedPubMedCentral Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B: Evidence b(i)ased medicine - selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ. 2003, 326: 1171-1173. 10.1136/bmj.326.7400.1171.PubMedPubMedCentral
7.
go back to reference Bero L, Oostvogel F, Bacchetti P, Lee K: Factors associated with findings of published trials of drug-drug comparisons: Why some statins appear more efficacious than others. PLoS Med. 2007, 4: e184-10.1371/journal.pmed.0040184.PubMedPubMedCentral Bero L, Oostvogel F, Bacchetti P, Lee K: Factors associated with findings of published trials of drug-drug comparisons: Why some statins appear more efficacious than others. PLoS Med. 2007, 4: e184-10.1371/journal.pmed.0040184.PubMedPubMedCentral
8.
go back to reference Johansen HK, Gøtzsche PC: Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA. 1999, 282: 1752-1759. 10.1001/jama.282.18.1752.PubMed Johansen HK, Gøtzsche PC: Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA. 1999, 282: 1752-1759. 10.1001/jama.282.18.1752.PubMed
9.
go back to reference Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R: Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008, 358: 252-260. 10.1056/NEJMsa065779.PubMed Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R: Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008, 358: 252-260. 10.1056/NEJMsa065779.PubMed
10.
go back to reference Rising K, Bacchetti P, Bero : Reporting bias in drug trials submitted to the Food and Drug Administration: a review of publication and presentation. PLoS Med. 2008, 5: e217-10.1371/journal.pmed.0050217.PubMedPubMedCentral Rising K, Bacchetti P, Bero : Reporting bias in drug trials submitted to the Food and Drug Administration: a review of publication and presentation. PLoS Med. 2008, 5: e217-10.1371/journal.pmed.0050217.PubMedPubMedCentral
11.
go back to reference Healy D: Let them eat Prozac. 2004, New York: New York University Press Healy D: Let them eat Prozac. 2004, New York: New York University Press
12.
go back to reference Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J: Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010, 303: 47-53. 10.1001/jama.2009.1943.PubMedPubMedCentral Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J: Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010, 303: 47-53. 10.1001/jama.2009.1943.PubMedPubMedCentral
13.
14.
go back to reference Healy D: Did regulators fail over selective serotonin reuptake inhibitors?. BMJ. 2006, 333: 92-95. 10.1136/bmj.333.7558.92.PubMedPubMedCentral Healy D: Did regulators fail over selective serotonin reuptake inhibitors?. BMJ. 2006, 333: 92-95. 10.1136/bmj.333.7558.92.PubMedPubMedCentral
15.
go back to reference Kendall T, McGoey L, Jackson E: If NICE was in the USA. Lancet. 2009, 374: 272-273. 10.1016/S0140-6736(09)60781-9.PubMed Kendall T, McGoey L, Jackson E: If NICE was in the USA. Lancet. 2009, 374: 272-273. 10.1016/S0140-6736(09)60781-9.PubMed
16.
go back to reference Chan A-W, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG: Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA. 2004, 291: 2457-2465. 10.1001/jama.291.20.2457.PubMed Chan A-W, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG: Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA. 2004, 291: 2457-2465. 10.1001/jama.291.20.2457.PubMed
17.
go back to reference Chan AW, Krleza-Jerić K, Schmid I, Altman DG: Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. CMAJ. 2004, 171: 735-740. 10.1503/cmaj.1041086.PubMedPubMedCentral Chan AW, Krleza-Jerić K, Schmid I, Altman DG: Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. CMAJ. 2004, 171: 735-740. 10.1503/cmaj.1041086.PubMedPubMedCentral
18.
go back to reference Chan A-W, Hróbjartsson A, Jørgensen KJ, Gøtzsche PC, Altman DG: Reporting of sample size calculations and data analysis methods in randomized trials: comparison of publications with protocols. BMJ. 2008, 337: 1404-1407. Chan A-W, Hróbjartsson A, Jørgensen KJ, Gøtzsche PC, Altman DG: Reporting of sample size calculations and data analysis methods in randomized trials: comparison of publications with protocols. BMJ. 2008, 337: 1404-1407.
19.
go back to reference Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K: Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst Rev. 2009, Art. No.: MR000006, 1 Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K: Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst Rev. 2009, Art. No.: MR000006, 1
20.
go back to reference Vedula SS, Bero L, Scherer RW, Dickersin K: Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med. 2009, 361: 1963-1971. 10.1056/NEJMsa0906126.PubMed Vedula SS, Bero L, Scherer RW, Dickersin K: Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med. 2009, 361: 1963-1971. 10.1056/NEJMsa0906126.PubMed
21.
go back to reference Jureidini JN, McHenry LB, Mansfield PR: Clinical trials and drug promotion: selective reporting of study 329. Int J Risk Safety Med. 2008, 20: 73-81. Jureidini JN, McHenry LB, Mansfield PR: Clinical trials and drug promotion: selective reporting of study 329. Int J Risk Safety Med. 2008, 20: 73-81.
22.
go back to reference McCormack K, Scott N, Grant A: Outcome reporting bias and individual patient data meta-analysis: a case study in surgery. 9th International Cochrane Colloquium: 9-13. 2001, 34-abstract P-005, Oct ; Lyon, France McCormack K, Scott N, Grant A: Outcome reporting bias and individual patient data meta-analysis: a case study in surgery. 9th International Cochrane Colloquium: 9-13. 2001, 34-abstract P-005, Oct ; Lyon, France
23.
go back to reference Moore TJ: Deadly medicine: why tens of thousands of heart patients died in America's worst drug disaster. 1995, New York: Simon & Schuster Moore TJ: Deadly medicine: why tens of thousands of heart patients died in America's worst drug disaster. 1995, New York: Simon & Schuster
24.
go back to reference Cowley AJ, Skene A, Stainer K, Hampton JR: The effect of lorcainide on arrhythmias and survival in patients with acute myocardial infarction: an example of publication bias. Int J Cardiol. 1993, 40: 161-166. 10.1016/0167-5273(93)90279-P.PubMed Cowley AJ, Skene A, Stainer K, Hampton JR: The effect of lorcainide on arrhythmias and survival in patients with acute myocardial infarction: an example of publication bias. Int J Cardiol. 1993, 40: 161-166. 10.1016/0167-5273(93)90279-P.PubMed
25.
26.
go back to reference Topol EJ: Failing the public health - rofecoxib, Merck, and the FDA. N Engl J Med. 2004, 351: 1707-1709. 10.1056/NEJMp048286.PubMed Topol EJ: Failing the public health - rofecoxib, Merck, and the FDA. N Engl J Med. 2004, 351: 1707-1709. 10.1056/NEJMp048286.PubMed
28.
go back to reference Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001, 286: 954-959. 10.1001/jama.286.8.954.PubMed Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001, 286: 954-959. 10.1001/jama.286.8.954.PubMed
29.
go back to reference Curfman GD, Morrissey S, Drazen JM: Expression of concern: Bombardier et al., "comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis". N Engl J Med. 2005, 353: 2813-2814. 10.1056/NEJMe058314.PubMed Curfman GD, Morrissey S, Drazen JM: Expression of concern: Bombardier et al., "comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis". N Engl J Med. 2005, 353: 2813-2814. 10.1056/NEJMe058314.PubMed
30.
go back to reference Curfman GD, Morrissey S, Drazen JM: Expression of concern reaffirmed. N Engl J Med. 2006, 354: 1193-10.1056/NEJMe068054.PubMed Curfman GD, Morrissey S, Drazen JM: Expression of concern reaffirmed. N Engl J Med. 2006, 354: 1193-10.1056/NEJMe068054.PubMed
33.
go back to reference de Andrade M: In clear sight. BMJ. 2009, 339: 538-541. de Andrade M: In clear sight. BMJ. 2009, 339: 538-541.
34.
go back to reference Hrachovec JB: Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA. 2001, 286: 2398-10.1001/jama.286.19.2398.PubMed Hrachovec JB: Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA. 2001, 286: 2398-10.1001/jama.286.19.2398.PubMed
35.
go back to reference Jüni P, Rutjes AW, Dieppe PA: Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?. BMJ. 2002, 324: 1287-1288. 10.1136/bmj.324.7349.1287.PubMedPubMedCentral Jüni P, Rutjes AW, Dieppe PA: Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?. BMJ. 2002, 324: 1287-1288. 10.1136/bmj.324.7349.1287.PubMedPubMedCentral
36.
go back to reference Jüni P, Reichenbach S, Egger M: COX 2 inhibitors, traditional NSAIDs, and the heart. BMJ. 2005, 330: 1342-1343. 10.1136/bmj.330.7504.1342.PubMedPubMedCentral Jüni P, Reichenbach S, Egger M: COX 2 inhibitors, traditional NSAIDs, and the heart. BMJ. 2005, 330: 1342-1343. 10.1136/bmj.330.7504.1342.PubMedPubMedCentral
37.
go back to reference Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R: Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med. 2006, 99: 132-140. 10.1258/jrsm.99.3.132.PubMedPubMedCentral Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R: Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med. 2006, 99: 132-140. 10.1258/jrsm.99.3.132.PubMedPubMedCentral
38.
go back to reference Braitwaite J: Corporate crime in the pharmaceutical industry. 1984, London: Routledge & Kegan Paul Braitwaite J: Corporate crime in the pharmaceutical industry. 1984, London: Routledge & Kegan Paul
39.
go back to reference Mundy A: Dispensing with the truth. 2001, New York: St. Martin's Press Mundy A: Dispensing with the truth. 2001, New York: St. Martin's Press
40.
go back to reference Avorn J: Powerful medicines: The benefits, risks, and costs of prescription drugs. 2005, New York: Vintage Books Avorn J: Powerful medicines: The benefits, risks, and costs of prescription drugs. 2005, New York: Vintage Books
41.
go back to reference Petersen M: Our daily meds. 2008, New York: Sarah Crichton Books Petersen M: Our daily meds. 2008, New York: Sarah Crichton Books
42.
go back to reference Avorn J: Dangerous deception - hiding the evidence of adverse drug effects. N Engl J Med. 2006, 355: 2169-2171. 10.1056/NEJMp068246.PubMed Avorn J: Dangerous deception - hiding the evidence of adverse drug effects. N Engl J Med. 2006, 355: 2169-2171. 10.1056/NEJMp068246.PubMed
43.
go back to reference Lurie P, Wolfe SM: Misleading data analyses in salmeterol (SMART) study. Lancet. 2005, 366: 1261-1262. 10.1016/S0140-6736(05)67518-6.PubMed Lurie P, Wolfe SM: Misleading data analyses in salmeterol (SMART) study. Lancet. 2005, 366: 1261-1262. 10.1016/S0140-6736(05)67518-6.PubMed
44.
go back to reference Nissen SE, Wolski K, Topol EJ: Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005, 294: 2581-2586. 10.1001/jama.294.20.joc50147.PubMed Nissen SE, Wolski K, Topol EJ: Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005, 294: 2581-2586. 10.1001/jama.294.20.joc50147.PubMed
45.
go back to reference Brophy JM: Selling safety - lessons from muraglitazar. JAMA. 2005, 294: 2633-2635. 10.1001/jama.294.20.jed50074.PubMed Brophy JM: Selling safety - lessons from muraglitazar. JAMA. 2005, 294: 2633-2635. 10.1001/jama.294.20.jed50074.PubMed
46.
go back to reference DeAngelis CD, Fontanarosa PB: Ensuring integrity in industry-sponsored research. JAMA. 2010, 303: 1196-1198. 10.1001/jama.2010.337.PubMed DeAngelis CD, Fontanarosa PB: Ensuring integrity in industry-sponsored research. JAMA. 2010, 303: 1196-1198. 10.1001/jama.2010.337.PubMed
48.
go back to reference Rosiglitazone Cohen: What went wrong?. BMJ. 2010, 341: 530-534. Rosiglitazone Cohen: What went wrong?. BMJ. 2010, 341: 530-534.
49.
go back to reference Bass A: Side effects - a prosecutor, a whistleblower, and a bestselling antidepressant on trial. 2008, Chapel Hill: Algonquin Books Bass A: Side effects - a prosecutor, a whistleblower, and a bestselling antidepressant on trial. 2008, Chapel Hill: Algonquin Books
50.
go back to reference Dyer O: GlaxoSmithKline to set up comprehensive online clinical trials register. BMJ. 2004, 329: 590-PubMedCentral Dyer O: GlaxoSmithKline to set up comprehensive online clinical trials register. BMJ. 2004, 329: 590-PubMedCentral
51.
go back to reference Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007, 356: 2457-2471. 10.1056/NEJMoa072761.PubMed Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007, 356: 2457-2471. 10.1056/NEJMoa072761.PubMed
52.
go back to reference Nissen SE: Setting the RECORD straight. JAMA. 2010, 303: 1194-1195. 10.1001/jama.2010.333.PubMed Nissen SE: Setting the RECORD straight. JAMA. 2010, 303: 1194-1195. 10.1001/jama.2010.333.PubMed
53.
go back to reference Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ: Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med. 2007, 357: 28-38. 10.1056/NEJMoa073394.PubMed Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ: Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med. 2007, 357: 28-38. 10.1056/NEJMoa073394.PubMed
54.
go back to reference Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ: Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009, 373: 2125-2135. 10.1016/S0140-6736(09)60953-3.PubMed Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ: Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009, 373: 2125-2135. 10.1016/S0140-6736(09)60953-3.PubMed
55.
go back to reference Psaty BM, Prentice RL: Minimizing bias in randomized trials: the importance of blinding. JAMA. 2010, 304: 793-794. 10.1001/jama.2010.1161.PubMed Psaty BM, Prentice RL: Minimizing bias in randomized trials: the importance of blinding. JAMA. 2010, 304: 793-794. 10.1001/jama.2010.1161.PubMed
56.
go back to reference Graham D, Gelperin K: More on advisory committee decision. BMJ. 2010, 341: 519- Graham D, Gelperin K: More on advisory committee decision. BMJ. 2010, 341: 519-
57.
go back to reference Cohen D: Complications: tracking down the data on oseltamivir. BMJ. 2009, 339: b5387-10.1136/bmj.b5387.PubMed Cohen D: Complications: tracking down the data on oseltamivir. BMJ. 2009, 339: b5387-10.1136/bmj.b5387.PubMed
58.
go back to reference Jefferson T, Doshi P, Heneghan C: Ensuring safe and effective drugs: Who can do what it takes?. BMJ. 2011, 342: c7258-10.1136/bmj.c7258.PubMed Jefferson T, Doshi P, Heneghan C: Ensuring safe and effective drugs: Who can do what it takes?. BMJ. 2011, 342: c7258-10.1136/bmj.c7258.PubMed
59.
go back to reference Friislund M: 10 år med Wikipedia. Berlingske Tidende. 2011, sektion:1-2 Friislund M: 10 år med Wikipedia. Berlingske Tidende. 2011, sektion:1-2
60.
go back to reference Walport M, Brest P: Sharing research data to improve public health. Lancet. 2011, 377: 537-539. 10.1016/S0140-6736(10)62234-9.PubMed Walport M, Brest P: Sharing research data to improve public health. Lancet. 2011, 377: 537-539. 10.1016/S0140-6736(10)62234-9.PubMed
61.
62.
go back to reference Ghersi D, Pang T: From Mexico to Mali: four years in the history of clinical trial registration. J Evidence-Based Med. 2009, 2: 1-7. 10.1111/j.1756-5391.2009.01014.x. Ghersi D, Pang T: From Mexico to Mali: four years in the history of clinical trial registration. J Evidence-Based Med. 2009, 2: 1-7. 10.1111/j.1756-5391.2009.01014.x.
66.
go back to reference Science, Technology and Innovation for the 21st Century. Meeting of the OECD Committee for Scientific and Technological Policy at Ministerial Level, 29-30 January 2004 - Final Communique. 2004 Science, Technology and Innovation for the 21st Century. Meeting of the OECD Committee for Scientific and Technological Policy at Ministerial Level, 29-30 January 2004 - Final Communique. 2004
67.
go back to reference Arzberger P, Schroeder P, Beaulieu A, Bowker G, Casey K, Laaksonen L, Moorman D, Uhlir P, Wouters P: Promoting access to public research data for scientific, economic, and social development. Data Science Journal. 2004, 3: 135-152. Arzberger P, Schroeder P, Beaulieu A, Bowker G, Casey K, Laaksonen L, Moorman D, Uhlir P, Wouters P: Promoting access to public research data for scientific, economic, and social development. Data Science Journal. 2004, 3: 135-152.
70.
go back to reference Communication from the Commission - Guidance on the information concerning paediatric clinical trials to be entered into the EU Database on Clinical Trials (EudraCT) and on the information to be made public by the European Medicines Agency (EMEA), in accordance with Article 41 of Regulation (EC) No 1901/2006. Communication from the Commission - Guidance on the information concerning paediatric clinical trials to be entered into the EU Database on Clinical Trials (EudraCT) and on the information to be made public by the European Medicines Agency (EMEA), in accordance with Article 41 of Regulation (EC) No 1901/2006.
73.
go back to reference The Food and Drug Administration (FDA) Amendment Act of 2007. Public Law 110-85--Sept 27. 2007 The Food and Drug Administration (FDA) Amendment Act of 2007. Public Law 110-85--Sept 27. 2007
74.
go back to reference Wieseler B, McGauran N, Kaiser T: Finding studies on reboxetine: a tale of hide and seek. BMJ. 2010, 341: c4942-10.1136/bmj.c4942.PubMed Wieseler B, McGauran N, Kaiser T: Finding studies on reboxetine: a tale of hide and seek. BMJ. 2010, 341: c4942-10.1136/bmj.c4942.PubMed
79.
go back to reference US CDC/ATSDR policy on releasing and sharing data. US CDC/ATSDR policy on releasing and sharing data.
80.
go back to reference Sharing research data to improve public health: full joint statement by funders of health research. The Wellcome Trust 2010. Sharing research data to improve public health: full joint statement by funders of health research. The Wellcome Trust 2010.
84.
go back to reference Groves T: Managing UK research data for future use. BMJ. 2009, 338: b1252-10.1136/bmj.b1252.PubMed Groves T: Managing UK research data for future use. BMJ. 2009, 338: b1252-10.1136/bmj.b1252.PubMed
85.
go back to reference Cowling BJ, Chan KH, Fang VJ, Cheng CK, Fung RO, Wai W, Sin J, Seto WH, Yung R, Chu DW, Chiu BC, Lee PW, Chiu MC, Lee HC, Uyeki TM, Houck PM, Peiris JS, Leung GM: Facemasks and hand hygiene to prevent influenza transmission in households: a cluster randomized trial. Ann Intern Med. 2009, 151: 437-446.PubMed Cowling BJ, Chan KH, Fang VJ, Cheng CK, Fung RO, Wai W, Sin J, Seto WH, Yung R, Chu DW, Chiu BC, Lee PW, Chiu MC, Lee HC, Uyeki TM, Houck PM, Peiris JS, Leung GM: Facemasks and hand hygiene to prevent influenza transmission in households: a cluster randomized trial. Ann Intern Med. 2009, 151: 437-446.PubMed
87.
go back to reference The Cochrane Collaboration Supports Prospective Registration of Clinical Trials. 26 July 2004. The Cochrane Collaboration Supports Prospective Registration of Clinical Trials. 26 July 2004.
88.
go back to reference Koehlmoos TP, Smith R: Big publishers cut access to journals in poor countries. Lancet. 2011, 377: 273-276. 10.1016/S0140-6736(11)60067-6.PubMed Koehlmoos TP, Smith R: Big publishers cut access to journals in poor countries. Lancet. 2011, 377: 273-276. 10.1016/S0140-6736(11)60067-6.PubMed
89.
go back to reference Regulation (EC) No 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access to European Parliament, Council and Commission documents. Official Journal of the European Communities, 31.5.2001:L 145/43-8. Regulation (EC) No 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access to European Parliament, Council and Commission documents. Official Journal of the European Communities, 31.5.2001:L 145/43-8.
90.
go back to reference Gøtzsche PC, Jørgensen AW: Opening up data at the European Medicines Agency. BMJ. 2011, 342: d2686-10.1136/bmj.d2686.PubMed Gøtzsche PC, Jørgensen AW: Opening up data at the European Medicines Agency. BMJ. 2011, 342: d2686-10.1136/bmj.d2686.PubMed
92.
go back to reference Abramson J: Overdo$ed America: The broken promise of American medicine. 2004, New York: Harper Collins Abramson J: Overdo$ed America: The broken promise of American medicine. 2004, New York: Harper Collins
95.
go back to reference Carpenter D, Zucker EJ, Avorn J: Drug-review deadlines and safety problems. N Engl J Med. 2008, 358: 1354-1361. 10.1056/NEJMsa0706341.PubMed Carpenter D, Zucker EJ, Avorn J: Drug-review deadlines and safety problems. N Engl J Med. 2008, 358: 1354-1361. 10.1056/NEJMsa0706341.PubMed
96.
go back to reference Carpenter D: Drug-review deadlines and safety problems (authors' reply). N Engl J Med. 2008, 359: 96-98. Carpenter D: Drug-review deadlines and safety problems (authors' reply). N Engl J Med. 2008, 359: 96-98.
100.
go back to reference Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005, 365: 475-481.PubMed Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005, 365: 475-481.PubMed
102.
go back to reference George J: Annas. Globalized clinical trials and informed consent. N Engl J Med. 2009, 360: 2050-2053. 10.1056/NEJMp0901474. George J: Annas. Globalized clinical trials and informed consent. N Engl J Med. 2009, 360: 2050-2053. 10.1056/NEJMp0901474.
104.
go back to reference Chalmers I, Glasziou P: Avoidable waste in the production and reporting of research evidence. Lancet. 2009, 374: 86-89. 10.1016/S0140-6736(09)60329-9.PubMed Chalmers I, Glasziou P: Avoidable waste in the production and reporting of research evidence. Lancet. 2009, 374: 86-89. 10.1016/S0140-6736(09)60329-9.PubMed
105.
go back to reference Wendler D, Krohmal B, Emanuel EJ, Grady C, ESPRIT Group: Why patients continue to participate in clinical research. Arch Intern Med. 2008, 168: 1294-1299. 10.1001/archinte.168.12.1294.PubMed Wendler D, Krohmal B, Emanuel EJ, Grady C, ESPRIT Group: Why patients continue to participate in clinical research. Arch Intern Med. 2008, 168: 1294-1299. 10.1001/archinte.168.12.1294.PubMed
106.
go back to reference Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan A-W: Constraints on publication rights in industry-initiated clinical trials. JAMA. 2006, 295: 1645-1646. 10.1001/jama.295.14.1645.PubMed Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan A-W: Constraints on publication rights in industry-initiated clinical trials. JAMA. 2006, 295: 1645-1646. 10.1001/jama.295.14.1645.PubMed
107.
go back to reference Grill M: Kranke Geschäfte: wie die Pharmaindustrie uns manipuliert. 2007, Hamburg: Rowohlt Verlag Grill M: Kranke Geschäfte: wie die Pharmaindustrie uns manipuliert. 2007, Hamburg: Rowohlt Verlag
108.
go back to reference Garattini S: Confidentiality. Lancet. 2003, 362: 1078-1079. 10.1016/S0140-6736(03)14424-8.PubMed Garattini S: Confidentiality. Lancet. 2003, 362: 1078-1079. 10.1016/S0140-6736(03)14424-8.PubMed
109.
go back to reference Eyding D, Lelgemann M, Grouven U, Härter M, Kromp M, Kaiser T, Kerekes MF, Gerken M, Wieseler B: Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ. 2010, 341: c4737-10.1136/bmj.c4737.PubMedPubMedCentral Eyding D, Lelgemann M, Grouven U, Härter M, Kromp M, Kaiser T, Kerekes MF, Gerken M, Wieseler B: Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ. 2010, 341: c4737-10.1136/bmj.c4737.PubMedPubMedCentral
110.
go back to reference Angell M: The truth about drug companies: How they deceive us and what to do about it. 2004, New York: Random House Angell M: The truth about drug companies: How they deceive us and what to do about it. 2004, New York: Random House
111.
go back to reference Goozner M: The $800 million pill: the truth behind the cost of new drugs. 2004, Berkeley: University of California Press Goozner M: The $800 million pill: the truth behind the cost of new drugs. 2004, Berkeley: University of California Press
112.
go back to reference Garattini S, Bertele V: Efficacy, safety, and cost of new anticancer drugs. BMJ. 2002, 325: 269-271. 10.1136/bmj.325.7358.269.PubMedPubMedCentral Garattini S, Bertele V: Efficacy, safety, and cost of new anticancer drugs. BMJ. 2002, 325: 269-271. 10.1136/bmj.325.7358.269.PubMedPubMedCentral
114.
go back to reference Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N: Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006, 355: 1018-1028. 10.1056/NEJMoa063842.PubMed Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N: Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006, 355: 1018-1028. 10.1056/NEJMoa063842.PubMed
115.
go back to reference Laine C, Horton R, DeAngelis CD, Drazen JM, Frizelle FA, Godlee F, Haug C, Hébert PC, Kotzin S, Marusic A, Sahni P, Schroeder TV, Sox HC, Van der Weyden MB, Verheugt FW: Clinical trial registration. Looking back and moving ahead. BMJ. 2007, 334: 1177-1178. 10.1136/bmj.39233.510810.80.PubMedPubMedCentral Laine C, Horton R, DeAngelis CD, Drazen JM, Frizelle FA, Godlee F, Haug C, Hébert PC, Kotzin S, Marusic A, Sahni P, Schroeder TV, Sox HC, Van der Weyden MB, Verheugt FW: Clinical trial registration. Looking back and moving ahead. BMJ. 2007, 334: 1177-1178. 10.1136/bmj.39233.510810.80.PubMedPubMedCentral
116.
go back to reference Savage CJ, Vickers AJ: Empirical study of data sharing by authors publishing in PLoS journals. PLoS ONE. 2009, 4: e7078-10.1371/journal.pone.0007078.PubMedPubMedCentral Savage CJ, Vickers AJ: Empirical study of data sharing by authors publishing in PLoS journals. PLoS ONE. 2009, 4: e7078-10.1371/journal.pone.0007078.PubMedPubMedCentral
117.
go back to reference Dwan K, Altman DG, Cresswell L, Blundell M, Gamble CL, Williamson PR: Comparison of protocols and registry entries to published reports for randomised controlled trials. Cochrane Database Syst Rev. 2011, Art. No.: MR000031, 1 Dwan K, Altman DG, Cresswell L, Blundell M, Gamble CL, Williamson PR: Comparison of protocols and registry entries to published reports for randomised controlled trials. Cochrane Database Syst Rev. 2011, Art. No.: MR000031, 1
118.
go back to reference Gøtzsche PC: Rational Diagnosis and Treatment. Evidence-Based Clinical Decision-Making, 4th edition. 2007, Chichester: Wiley Gøtzsche PC: Rational Diagnosis and Treatment. Evidence-Based Clinical Decision-Making, 4th edition. 2007, Chichester: Wiley
119.
go back to reference Collier J: Big pharma and the UK government. . Lancet. 2006, 367: 97-98. 10.1016/S0140-6736(06)67943-9.PubMed Collier J: Big pharma and the UK government. . Lancet. 2006, 367: 97-98. 10.1016/S0140-6736(06)67943-9.PubMed
121.
go back to reference Danish Research Ethics Committee System. Recommendation No. 20: controlled clinical trials - the influence of existing and newly acquired scientific results on the research ethical evaluation. Copenhagen: Danish Research Ethics Committee System; 1997. Danish Research Ethics Committee System. Recommendation No. 20: controlled clinical trials - the influence of existing and newly acquired scientific results on the research ethical evaluation. Copenhagen: Danish Research Ethics Committee System; 1997.
122.
go back to reference Goldbeck-Wood S: Denmark takes a lead on research ethics. BMJ. 1998, 316: 1185- Goldbeck-Wood S: Denmark takes a lead on research ethics. BMJ. 1998, 316: 1185-
123.
go back to reference Savulescu J, Chalmers I, Blunt J: Are research ethics committees behaving unethically? Some suggestions for improving performance and accountability. BMJ. 1996, 313: 1390-1393. 10.1136/bmj.313.7069.1390.PubMedPubMedCentral Savulescu J, Chalmers I, Blunt J: Are research ethics committees behaving unethically? Some suggestions for improving performance and accountability. BMJ. 1996, 313: 1390-1393. 10.1136/bmj.313.7069.1390.PubMedPubMedCentral
124.
go back to reference Baum ML, Anish DS, Chalmers TC, Sacks HS, Smith H, Fagerstrom RM: A survey of clinical trials of antibiotic prophylaxis in colon surgery: evidence against further use of no-treatment controls. N Engl J Med. 1981, 305: 795-799. 10.1056/NEJM198110013051404.PubMed Baum ML, Anish DS, Chalmers TC, Sacks HS, Smith H, Fagerstrom RM: A survey of clinical trials of antibiotic prophylaxis in colon surgery: evidence against further use of no-treatment controls. N Engl J Med. 1981, 305: 795-799. 10.1056/NEJM198110013051404.PubMed
125.
go back to reference Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC: A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. . JAMA. 1992, 268: 240-248. 10.1001/jama.268.2.240.PubMed Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC: A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. . JAMA. 1992, 268: 240-248. 10.1001/jama.268.2.240.PubMed
126.
go back to reference Fergusson D, Glass KC, Hutton B, Shapiro S: Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding. ? Clin Trials. 2005, 2: 218-229. 10.1191/1740774505cn085oa. discussion 229-232PubMed Fergusson D, Glass KC, Hutton B, Shapiro S: Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding. ? Clin Trials. 2005, 2: 218-229. 10.1191/1740774505cn085oa. discussion 229-232PubMed
127.
go back to reference Robinson KA, Goodman SN: A systematic examination of the citation of prior research in reports of randomized, controlled trials. Ann Intern Med. 2011, 154: 50-55.PubMed Robinson KA, Goodman SN: A systematic examination of the citation of prior research in reports of randomized, controlled trials. Ann Intern Med. 2011, 154: 50-55.PubMed
128.
go back to reference Clinard MB, Brissette J, Petrashek D, Harries E: Illegal corporate behaviour. 1979, Washington, D.C.: Law Enforcement Assistance Administration Clinard MB, Brissette J, Petrashek D, Harries E: Illegal corporate behaviour. 1979, Washington, D.C.: Law Enforcement Assistance Administration
130.
go back to reference Kassirer JP: On the take: how medicine's complicity with big business can endanger your health. 2005, Oxford: Oxford University Press Kassirer JP: On the take: how medicine's complicity with big business can endanger your health. 2005, Oxford: Oxford University Press
131.
go back to reference Nina Vinther Andersen: Vores piller. 2009, København: Tiderne Skifter Nina Vinther Andersen: Vores piller. 2009, København: Tiderne Skifter
132.
go back to reference Brody Howard: Hooked. Ethics, the medical profession, and the pharmaceutical industry. 2007, Lanham: Rowman & Littlefield Brody Howard: Hooked. Ethics, the medical profession, and the pharmaceutical industry. 2007, Lanham: Rowman & Littlefield
133.
go back to reference Marsa Linda: Prescription for profits. How the pharmaceutical industry bankrolled the unholy marriage between science and business. 1997, New York: Scribner Marsa Linda: Prescription for profits. How the pharmaceutical industry bankrolled the unholy marriage between science and business. 1997, New York: Scribner
134.
go back to reference Abraham John: Science, Politics, and the Pharmaceutical Industry. 1995, London: UCL Press Abraham John: Science, Politics, and the Pharmaceutical Industry. 1995, London: UCL Press
135.
go back to reference Brownlee Shannon: Overtreated. Why too much medicine is making us sicker and poorer. 2008, New York, Bloomsbury Brownlee Shannon: Overtreated. Why too much medicine is making us sicker and poorer. 2008, New York, Bloomsbury
136.
go back to reference Moynihan & Cassels: Selling sickness. How the world's biggest pharmaceutical companies are turning us all into patients. 2005, New York: Nation Books Moynihan & Cassels: Selling sickness. How the world's biggest pharmaceutical companies are turning us all into patients. 2005, New York: Nation Books
137.
go back to reference Rost Peter: The whistleblower, confessions of a healthcare hitman. 2006, New York: Soft Skull Press Rost Peter: The whistleblower, confessions of a healthcare hitman. 2006, New York: Soft Skull Press
139.
go back to reference Tanne JH: Pfizer pays record fine for off-label promotion of four drugs. BMJ. 2009, 339: b3657-10.1136/bmj.b3657. Tanne JH: Pfizer pays record fine for off-label promotion of four drugs. BMJ. 2009, 339: b3657-10.1136/bmj.b3657.
141.
go back to reference Hrynaszkiewicz I, Norton ML, Vickers AJ, Altman DG: Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers. BMJ. 2010, 340: c181-10.1136/bmj.c181.PubMedPubMedCentral Hrynaszkiewicz I, Norton ML, Vickers AJ, Altman DG: Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers. BMJ. 2010, 340: c181-10.1136/bmj.c181.PubMedPubMedCentral
Metadata
Title
Why we need easy access to all data from all clinical trials and how to accomplish it
Author
Peter C Gøtzsche
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Trials / Issue 1/2011
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/1745-6215-12-249

Other articles of this Issue 1/2011

Trials 1/2011 Go to the issue